Hearing on "Policies to Protect Our Communities From Illicit Drug Threats"

The Subcommittee on Health of the Committee on Energy and Commerce held a hearing on Thursday, March 26, 2026, at 2 p.m. (EDT) in the John D. Dingell Room, 2123 Rayburn House Office Building.  The hearing is entitled "Policies to Protect Our Communities From Illicit Drug Threats."

Key Documents 

Opening Statement from Full Committee Ranking Member Pallone as prepared for delivery 

Opening Statement from Subcommittee Ranking Member DeGette as prepared for delivery

Livestream

Witnesses

Scott Oulton

President

INTR3PID Solutions LLC

Testimony

K. Fred Gingrich II, DVM

Executive Director

American Association of Bovine Practitioners

Testimony

Dennis Lemma

Sheriff; Former President

Seminole County, Florida; Major County Sheriffs of America

Testimony

Nabarun Dasgupta, PhD, MPH

Senior Scientist and Gillings Innovation Fellow

University of North Carolina at Chapel Hill

Testimony

Yngvild Olsen, MD, MPH

Former Director of the Center for Substance Abuse Treatment; National Advisor 

Substance Abuse and Mental Health Services Administration; Manatt Health

Testimony 

Legislation 

• H.R. 1266, the Combatting Illicit Xylazine Act
• H.R. 5630, To amend the Public Health Service Act to require additional information in State plans for Substance Use Prevention, Treatment, and Recovery Services block grants
• H.R. 5629, To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.
• H.R. 2004, Tyler's Law
• H.R. 7970, the STOP Nitazenes Act
• H.R. 8000, the END 7-OH Act
• H.R. 7184, the PRESS Act
• H.R. 8005, the Stop Pills That Kill Act
• H.R. 5880, the Fight Illicit Pill Presses Act
• H.R. 1227, the Alternatives to Pain Act
• H.R. 2715, the Destruction of Hazardous Imports Act
• H.R. 1561, the ALERT Communities Act
• H.R. 7994, the HERO Act
• H.R. 7407, the Prohibiting Tianeptine and Other Dangerous Products Act of 2026